Dengue vaccine vs. Circulating serotype: a discussion of vaccine coverage according to the epidemiology of regions in Brazil
Autor(a) principal: | |
---|---|
Data de Publicação: | 2024 |
Outros Autores: | |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Revista JRG de Estudos Acadêmicos |
Texto Completo: | http://revistajrg.com/index.php/jrg/article/view/951 |
Resumo: | Arboviruses pose a significant challenge to public health, manifesting through nonspecific symptoms such as fever, headache, myalgia, body pain, as well as pain behind the eyes. Additionally, dengue can progress to more severe forms, such as dengue hemorrhagic fever or shock, especially in cases of sequential infections by serotypes to which the individual has not yet been exposed. In this study, 54 documents were consulted, including scientific articles, epidemiological bulletins, publications on official websites, and technical data sheets, in order to better understand the panorama of this arbovirus. We observed that in different regions of the country, all serotypes are registered to be in circulation, however, the predominance of one serotype over the other may exist. Regarding the vaccines available in Brazil, such as Dengvaxia® and QDenga®, both approved by ANVISA, it was decided to include QDenga® in the National Immunization Program (PNI). This choice was based on its ability to be administered to both seropositive and seronegative individuals, and its efficacy against all four serotypes simultaneously, prioritizing the most vulnerable groups. This decision was especially guided for regions where new dengue subtypes are emerging, and cases are increasing. As indicated by the analyzed publications, QDenga® proves to be promising in the Brazilian context, standing out for its efficacy and flexibility of use. These results underscore the ongoing importance of epidemiological surveillance and the development of prevention and control strategies to address vector-borne diseases. |
id |
JRG_440d5b58de95d32621515228ef6b1ffd |
---|---|
oai_identifier_str |
oai:ojs2.revistajrg.com:article/951 |
network_acronym_str |
JRG |
network_name_str |
Revista JRG de Estudos Acadêmicos |
repository_id_str |
|
spelling |
Dengue vaccine vs. Circulating serotype: a discussion of vaccine coverage according to the epidemiology of regions in BrazilVacina da dengue x sorotipo circulante: uma discussão da cobertura vacinal de acordo com a epidemiologia das regiões do BrasilDengueVacinaEpidemiologiaArbovírusDengueVacinnesEpidemiologyArbovirusArboviruses pose a significant challenge to public health, manifesting through nonspecific symptoms such as fever, headache, myalgia, body pain, as well as pain behind the eyes. Additionally, dengue can progress to more severe forms, such as dengue hemorrhagic fever or shock, especially in cases of sequential infections by serotypes to which the individual has not yet been exposed. In this study, 54 documents were consulted, including scientific articles, epidemiological bulletins, publications on official websites, and technical data sheets, in order to better understand the panorama of this arbovirus. We observed that in different regions of the country, all serotypes are registered to be in circulation, however, the predominance of one serotype over the other may exist. Regarding the vaccines available in Brazil, such as Dengvaxia® and QDenga®, both approved by ANVISA, it was decided to include QDenga® in the National Immunization Program (PNI). This choice was based on its ability to be administered to both seropositive and seronegative individuals, and its efficacy against all four serotypes simultaneously, prioritizing the most vulnerable groups. This decision was especially guided for regions where new dengue subtypes are emerging, and cases are increasing. As indicated by the analyzed publications, QDenga® proves to be promising in the Brazilian context, standing out for its efficacy and flexibility of use. These results underscore the ongoing importance of epidemiological surveillance and the development of prevention and control strategies to address vector-borne diseases.Arboviroses representam um desafio significativo para a saúde pública, manifestando-se através de sintomas inespecíficos como febre, dor de cabeça, mialgia e dor no corpo, com enfase atrás dos olhos. Além disso, a dengue pode evoluir para formas mais graves, como dengue hemorrágica ou choque, especialmente em casos de infecções sequenciais por sorotipos aos quais o indivíduo ainda não foi exposto. Neste estudo 54 documentos foram consultados, incluindo artigos científicos, boletins epidemiológicos, publicações em sites oficiais e fichas técnicas, a fim de compreender melhor o panorama desta arbovirose. Observamos que, nas diferentes regiões do país todos os sorotipos têm registro de circulação, no entanto a predominância de algum sorotipo em relação ao outro pode existir. Quanto às vacinas disponíveis no Brasil, como a Dengvaxia® e a QDenga®, ambas aprovadas pela ANVISA, optou-se pela inclusão da QDenga® no Programa Nacional de Imunizações (PNI). Essa escolha baseou-se na sua capacidade de ser administrada tanto em soropositivos quanto em soronegativos, e sua eficácia para simultaneamente quatro sorotipos, priorizando os grupos mais vulneráveis. Tal decisão foi orientada especialmente para regiões onde novos subtipos de dengue estão emergindo, e casos aumentados. Conforme indicam as publicações analisadas, a QDenga® mostra-se promissora no contexto brasileiro, destacando-se pela sua eficácia e flexibilidade de uso. Esses resultados ressaltam a importância contínua da vigilância epidemiológica e do desenvolvimento de estratégias de prevenção e controle para enfrentar as doenças transmitidas por vetores.Editora JRG2024-03-05info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArtigo avaliado pelos Paresapplication/pdfhttp://revistajrg.com/index.php/jrg/article/view/95110.55892/jrg.v7i14.951ark:/57118/JRG.v7i14.951JRG Journal of Academic Studies; Vol. 7 No. 14 (2024): JRG Journal of Academic Studies; e14951JRG Journal of Academic Studies ; Vol. 7 Núm. 14 (2024): Revista JRG de Estudos Acadêmicos; e14951JRG Journal of Academic Studies; V. 7 N. 14 (2024): Revista JRG de Estudos Acadêmicos; e14951Revista JRG de Estudos Acadêmicos ; v. 7 n. 14 (2024): Revista JRG de Estudos Acadêmicos; e149512595-1661ark:/57118/jrg.v7i14reponame:Revista JRG de Estudos Acadêmicosinstname:Editora JRGinstacron:JRGporhttp://revistajrg.com/index.php/jrg/article/view/951/846https://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessOliveira, Cintia Cryslaine da Silva deLira Neto, Paulo de Oliveira Paes de 2024-02-24T23:07:57Zoai:ojs2.revistajrg.com:article/951Revistahttp://revistajrg.com/index.php/jrgPRIhttp://revistajrg.com/index.php/jrg/oaiprofessorjonas@gmail.com||2595-16612595-1661opendoar:2024-02-24T23:07:57Revista JRG de Estudos Acadêmicos - Editora JRGfalse |
dc.title.none.fl_str_mv |
Dengue vaccine vs. Circulating serotype: a discussion of vaccine coverage according to the epidemiology of regions in Brazil Vacina da dengue x sorotipo circulante: uma discussão da cobertura vacinal de acordo com a epidemiologia das regiões do Brasil |
title |
Dengue vaccine vs. Circulating serotype: a discussion of vaccine coverage according to the epidemiology of regions in Brazil |
spellingShingle |
Dengue vaccine vs. Circulating serotype: a discussion of vaccine coverage according to the epidemiology of regions in Brazil Oliveira, Cintia Cryslaine da Silva de Dengue Vacina Epidemiologia Arbovírus Dengue Vacinnes Epidemiology Arbovirus |
title_short |
Dengue vaccine vs. Circulating serotype: a discussion of vaccine coverage according to the epidemiology of regions in Brazil |
title_full |
Dengue vaccine vs. Circulating serotype: a discussion of vaccine coverage according to the epidemiology of regions in Brazil |
title_fullStr |
Dengue vaccine vs. Circulating serotype: a discussion of vaccine coverage according to the epidemiology of regions in Brazil |
title_full_unstemmed |
Dengue vaccine vs. Circulating serotype: a discussion of vaccine coverage according to the epidemiology of regions in Brazil |
title_sort |
Dengue vaccine vs. Circulating serotype: a discussion of vaccine coverage according to the epidemiology of regions in Brazil |
author |
Oliveira, Cintia Cryslaine da Silva de |
author_facet |
Oliveira, Cintia Cryslaine da Silva de Lira Neto, Paulo de Oliveira Paes de |
author_role |
author |
author2 |
Lira Neto, Paulo de Oliveira Paes de |
author2_role |
author |
dc.contributor.author.fl_str_mv |
Oliveira, Cintia Cryslaine da Silva de Lira Neto, Paulo de Oliveira Paes de |
dc.subject.por.fl_str_mv |
Dengue Vacina Epidemiologia Arbovírus Dengue Vacinnes Epidemiology Arbovirus |
topic |
Dengue Vacina Epidemiologia Arbovírus Dengue Vacinnes Epidemiology Arbovirus |
description |
Arboviruses pose a significant challenge to public health, manifesting through nonspecific symptoms such as fever, headache, myalgia, body pain, as well as pain behind the eyes. Additionally, dengue can progress to more severe forms, such as dengue hemorrhagic fever or shock, especially in cases of sequential infections by serotypes to which the individual has not yet been exposed. In this study, 54 documents were consulted, including scientific articles, epidemiological bulletins, publications on official websites, and technical data sheets, in order to better understand the panorama of this arbovirus. We observed that in different regions of the country, all serotypes are registered to be in circulation, however, the predominance of one serotype over the other may exist. Regarding the vaccines available in Brazil, such as Dengvaxia® and QDenga®, both approved by ANVISA, it was decided to include QDenga® in the National Immunization Program (PNI). This choice was based on its ability to be administered to both seropositive and seronegative individuals, and its efficacy against all four serotypes simultaneously, prioritizing the most vulnerable groups. This decision was especially guided for regions where new dengue subtypes are emerging, and cases are increasing. As indicated by the analyzed publications, QDenga® proves to be promising in the Brazilian context, standing out for its efficacy and flexibility of use. These results underscore the ongoing importance of epidemiological surveillance and the development of prevention and control strategies to address vector-borne diseases. |
publishDate |
2024 |
dc.date.none.fl_str_mv |
2024-03-05 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Artigo avaliado pelos Pares |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://revistajrg.com/index.php/jrg/article/view/951 10.55892/jrg.v7i14.951 ark:/57118/JRG.v7i14.951 |
url |
http://revistajrg.com/index.php/jrg/article/view/951 |
identifier_str_mv |
10.55892/jrg.v7i14.951 ark:/57118/JRG.v7i14.951 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
http://revistajrg.com/index.php/jrg/article/view/951/846 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Editora JRG |
publisher.none.fl_str_mv |
Editora JRG |
dc.source.none.fl_str_mv |
JRG Journal of Academic Studies; Vol. 7 No. 14 (2024): JRG Journal of Academic Studies; e14951 JRG Journal of Academic Studies ; Vol. 7 Núm. 14 (2024): Revista JRG de Estudos Acadêmicos; e14951 JRG Journal of Academic Studies; V. 7 N. 14 (2024): Revista JRG de Estudos Acadêmicos; e14951 Revista JRG de Estudos Acadêmicos ; v. 7 n. 14 (2024): Revista JRG de Estudos Acadêmicos; e14951 2595-1661 ark:/57118/jrg.v7i14 reponame:Revista JRG de Estudos Acadêmicos instname:Editora JRG instacron:JRG |
instname_str |
Editora JRG |
instacron_str |
JRG |
institution |
JRG |
reponame_str |
Revista JRG de Estudos Acadêmicos |
collection |
Revista JRG de Estudos Acadêmicos |
repository.name.fl_str_mv |
Revista JRG de Estudos Acadêmicos - Editora JRG |
repository.mail.fl_str_mv |
professorjonas@gmail.com|| |
_version_ |
1797068983266967552 |